News and Events

Hatchtech Announces Successful Results from Phase 2 Ovicidal Study

21/10/2014 | Press Releases

21st October 2014, Melbourne Australia

Specialty pharmaceutical company Hatchtech Pty Ltd today announced succesful completion of a Phase 2 clinical trial evaluating the ovicidal efficacy (ability to kill lice eggs) of a single 10 minute application of Xeglyze Lotion developed as a treatment for head lice infestation.


Hatchtech Announces Successful Phase 3 Results

2/09/2014 | Press Releases

2nd September 2014 Melbourne, Australia

Specialty pharmaceutical company Hatchtech Pty Ltd today announced successful completion of its two pivotal Phase 3 clinical studies evaluating Xeglyze Lotion (formerly DeOvo Lotion) as a potential treatment for head lice infestation.


Hatchtech Receives SPA and Announces Patent Grants

11/12/2013 | Press Releases

HATCHTECH RECEIVES FDA SPECIAL PROTOCOL AGREEMENT OF DEOVO PHASE III STUDIES AND STRENGTHENS PATENT PORTFOLIO

Press Release





 


Hatchtech Completes $12.6m Capital Raise, Secures Funds for Phase III and NDA Submission

31/10/2013 | Press Releases

Hatchtech today announced the completion of a $12.6m capital raise to fund the Phase III clinical trial and NDA submission.  The company also announced several changes to the composition of its Board.

Download PDF


Hatchtech appoints Hugh Alsop as CEO

13/03/2013 | Press Releases

Specialty pharmaceutical company Hatchtech Pty Ltd is pleased to announce the appointment of former Phosphagenics Vice President Mr Hugh Alsop as the company’s new Chief Executive Officer

Download PDF


Categories